2 results match your criteria: "Department of Ophthalmology at Rush University Medical Center[Affiliation]"
Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis.
Can J Ophthalmol
June 2023
Retina Consultants of Texas; Retina Consultants of America; Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX.
Objective: To evaluate treatment patterns and outcomes of patients in the United States who received antivascular endothelial growth factor (anti-VEGF) agents for wet age-related macular degeneration (AMD).
Design: Retrospective study PARTICIPANTS: Patients with wet AMD.
Methods: Using the Intelligent Research in Sight Registry, we studied patients with wet AMD who received ≥1 anti-VEGF injection, who were ≥50 years old, and with ≥1.
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
JAMA Ophthalmol
January 2022
Department of Ophthalmology at Rush University Medical Center, Chicago, Illinois.
Importance: Limited data exist on the real-world safety outcomes of patients with neovascular age-related macular degeneration treated with brolucizumab (Beovu).
Objective: To determine the real-world incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and/or retinal vascular occlusion (RO), for patients with neovascular age-related macular degeneration who underwent brolucizumab treatment. Additionally, potential risk factors associated with these adverse events were evaluated.